Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.

The significant metastatic potential of uveal melanoma (UVM) lends to high mortality. Even with successful local tumor treatment, many patients will develop metastatic disease. The present study aims to elucidate the relationship between tumor-infiltrating immune cell (TIIC) diversity and survival to identify potential therapeutic targets and improve UVM prognosis.

There is striking clinical, histological, and molecular diversity observed across melanocytic tumors. Activating mutations in BRAF and NRAS are well-established initiators of benign melanocytic nevi and melanoma. However, accumulating evidence reveals that the biological outcome after oncogene activation is dependent on cellular state differences that vary by anatomic site, developmental timing, and cell of origin.

Melanoma is a strongly incursive cancer situated in the skin with narrow consecutive therapies. The goal of this article is to reveal some of the latest advances in using hydrogel for cancer especially melanoma therapy. Biocompatible brush biopolymer (linear dextrin) graft with polyurethane is developed for monitoring the hydrophilic and hydrophobic equipoise for regulating the delivery of drug to the target region. Drug incorporated brush copolymers upon embedded in gelating agent (methyl cellulose) develop an injectable hydrogel with potential